Abstract
7 patients with relapsing-remitting multiple sclerosis (MS) were subjected to an intensive course of intravenous (I.V.) cyclophosphamide (CY) therapy. All patients received induction therapy with 11 daily doses of 300 mg/m2 and then a single dose every six months for three years. After one year of follow-up all patients showed a decrease in relapse rate (0.57.57); in the two subsequent years of follow-up 2 patients showed a mild worsening while the others were clinically stable.
As suggested by others, our results indicate that I.V. CY therapy may influence the clinical course of relapsing-remitting MS.
Sommario
Sette pazienti affetti da Sclerosi Multipla di tipo remittente sono stati sottoposti a terapia immunosoppressiva con ciclofosfamide. Il trattamento consisteva di un ciclo di induzione con dosi di 300 mg/m2 di ciclofosfamide e.v. somminsstrate giornalmente per 11 giorni e di successive singole dosi di mantenimento di 300 mg/m2 somministrate ogni 6 mesi per un periodo di 3 anni.
Non sono stati osservati gravi effetti collaterali durante lo studio.
Dopo il primo anno di trattamento tutti i pazienti hanno mostrato miglioramento nella frequenza di ricaduta; nei due anni successivi 4 pazienti sono rimasti stabili mentre gli altri hanno mostrato un nuovo peggioramento. Come indicato da altri Autori, i risultati dello studio indicano che la terapia immunosoppressiva con ciclofosfamide ad alte dosi non presenta gravi effetti collaterali e può modificare il decorso della Sclerosi Multipla di tipo remittente.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Austin H. A., Klippel J.H., Balow J.E. et al.:Therapy of lupus nephritis: controlled trial of prednisone and citotoxic drugs. N. Engl J Med 314:614–619, 1986
Carter JL, Dawson D.M., Hafler D.A. et al:Five-years experience with intensive immunosuppression in progressive multiple sclerosis using high dose IV cyclophosphsmide plus ACTH. Neurology 36 (suppl 1):284, 1986.
Confavreux C, Aimard G., DevicM.:Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103:281–300, 1980.
Godkin D.E., Plencner S., Palmer-Sawerud J. et al.:Cyclophosphamide in chronic progressive multiple sclerosis, maintenance vs non-maintenance therapy. Arch Neurol 44: 1096–1104, 1987.
Gonsette R. E., Demonty L., Delmotte P.:Intensive immunosuppression with cyclophosphamide in multiple sclerosis: a follow-up of 110 patients for two to six years. J. Neurol; 214:173–181, 1977
Hauser S., Dawon D., Weiner H.L., et al.:Intensive immunosuppression in progressive multiple sclerosis: A randomized three arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH. N. Engl. J. Med. 308:173–180, 1983.
Hommes O.R., Lamers K.J.B., Reekers P.:Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J. Neurol. 1980: 223:177–190.
Khatri B.O., McQuillel M.D., Harrington G.J. et al.:Chronic progressive multiple sclerosis: Double blinded controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 35:312–319, 1985.
Killian J.M., Bresler R.B., Armstrong R.M.:A controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch. Neurol. 45:27–30, 1988.
Kurzke J.F.:Rating neurological impairment in MS: an expanded disability status scale. Neurology 33:1444–1452, 1983.
McAlpine D., Lumsden C.E., Acheson E.D.:Multiple sclerosis: a reappraisal, Edimburgh, Churchill Livingstone 1972.
McDonald W.I., Halliday A.M.:Diagnosis and classification of multiple sclerosis. Br. Med. Bull 3:4–8, 1975.
McFarlin D.E., McFarland H.F.:Multiple Sclerosis: New. Engl. J. Med. 19:1183–1188, 1982.
Mertin J., Kremer M., Knight S.C. et al.:Doubleblind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. Lancet 2:351–353, 1982.
Myers L.W., Fahey J.L., Moody D.J. et al.:Cyclophosphamide “pulses” in chronic progresive multiple sclerosis. A preliminary clinical trial. Arch. Neurol 44:829–832, 1987.
Theys P., Gosseye-Lissoir F., Ketelaer P. et al.:short-term intensive cyclophosphamide treatment in multiple sclerosis. J. Neurol. 225:119–134, 1981.
Tindall R.S., Walker J.I., Ehle A.L. et al.:Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone. Neurology 32:739–743, 1982.
Weiner H.L., Hauser S.L.:Immunoregulation in neurological disease. Annal. Neurol. 11:437–49, 1982.
Weiner H.L., Hauser S.L., Hafler D.A., et al.:The use of cyclophosphamide in the treatment of multiple sclerosis. Ann NY Acad Sci 436:373–381, 1985.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
D'Andrea, F., D'Aurizio, C., Marini, C. et al. Cyclophosphamide in relapsing remitting multiple sclerosis. Ital J Neuro Sci 11, 271–274 (1990). https://doi.org/10.1007/BF02333857
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02333857